• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: bictegravir, emtricitabine, and tenofovir alafenamide
Trade Name: Biktarvy
Date Designated: 05/17/2017
Orphan Designation: Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients
Orphan Designation Status: Designated/Approved
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, California 94404
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: bictegravir, emtricitabine, and tenofovir alafenamide
Trade Name: Biktarvy
Marketing Approval Date: 06/18/2019
Approved Labeled Indication: BIKTARVY® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral with no history of treatment failure and no known substitutions associated with resistance to the individual components o
Exclusivity End Date: 06/18/2026 
Exclusivity Protected Indication* :  As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral with no history of treatment failure and no known substitutions associated with resistance to the individual components of
2 Generic Name: bictegravir, emtricitabine, and tenofovir alafenamide
Trade Name: Biktarvy
Marketing Approval Date: 10/07/2021
Approved Labeled Indication: As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy
Exclusivity End Date: 10/07/2028 
Exclusivity Protected Indication* :  As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing 14 kg to less than 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-